• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Blocking toxic-protein production in ALS

Bioengineer by Bioengineer
January 22, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An approved drug that blocks an integrated stress response shows promise in preliminary tests against ALS and frontotemporal dementia

PHILADELPHIA — Patients with ALS frequently have a string of repeated DNA code in the cells of their brain, carrying hundreds to thousands of copies within the gene C9orf72. New research looks at what triggers these repeated sequences to eventually produce the toxic proteins that are associated with ALS, frontotemporal dementia, and other neurodegenerative diseases in patients carrying the C9orf72 mutation, the most common cause of inherited ALS. The work finds that neuronal excitation and stress trigger the protein production in cells, and reveals that targeting this stress response with a known drug could reduce toxic protein production.

“Understanding what triggers toxic proteins production helped us hone in on drugs that could block them in laboratory tests,” said co-senior author Aaron Haeusler, PhD, Assistant Professor of Neuroscience within the Vickie & Jack Farber Institute for Neuroscience and the Weinberg ALS Center at Jefferson (Philadelphia University + Thomas Jefferson University). The research was published in EMBO Molecular Medicine.

Through a collaboration with co-lead investigator Davide Trotti, PhD, and co-author Piera Pasinelli, PhD, who leads the Jefferson Weinberg ALS Center, Dr. Haeusler and colleagues tested what causes the repeat DNA sequences within C9orf72 to activate and produce toxic protein. Suspecting stressors as a possible trigger, the investigators tested a number of agents that cause neurons to turn on the stress responses. Indeed, many of these also initiated production of toxic protein. The researchers also showed that neuronal over-excitation, similar to what happens during a seizure, also triggered the protein production.

“Both cellular stress and over-excitation eventually converge into the integrated stress response,” said first author Thomas Westergard, a graduate student in Dr. Trotti’s lab.

Once the integrated stress response is activated, it’s difficult to stop the production of these toxic proteins. But honing in on this over-arching cellular mechanism offered the researchers a glimpse into specific methods that might block the neuron-damaging response.

The drug trazodone, which is approved for the treatment of depression, is known to act on parts of the integrated stress response. So, the researchers tested the drug in their models of disease, and found that it could indeed block production of toxic protein in a cellular model that contained the repeat mutations.

“This is a significant step forward in our collaborative approach,” said Dr. Pasinelli. “Working together allowed us to speed up the research process getting from the identification of the “pathogenic stress” to testing a potentially useful drug. ALS is a complex and heterogenous disease that needs this collaborative approach, with each lab contributing its own expertise, to fill the gaps and to put together this complex puzzle in a systematic and efficient way,”

The researchers are now expanding their research to screen for other molecules that might work better than the drug trazodone.

###

The work was supported NIH (R21-NS090912) (4R00NS091486-03), Muscular Dystrophy Association, the Robert Packard Center for ALS Research, and Farber Family Foundation grants supported this work. The authors report no conflicts of interest.

Article Reference: Thomas Westergard, Kevin McAvoy, Katelyn Russell, Xinmei Wen, Yu Pang, Brandie Morris, Piera Pasinelli, Davide Trotti, Aaron Haeusler, “Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress,” EMBO Molecular Medicine, DOI: 10.15252/emmm.201809423, 2019.

Media Contact: Edyta Zielinska, 215-955-7359, edyta.zielinska@jefferson.edu.

Media Contact
Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-7359
http://dx.doi.org/10.15252/emmm.201809423

Tags: BiologyCell BiologyMolecular Biologyneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Single-Cell Sequencing Uncovers How STAP2 Drives Diabetic Retinal Vascular Dysfunction

Single-Cell Sequencing Uncovers How STAP2 Drives Diabetic Retinal Vascular Dysfunction

November 22, 2026
Heterozygous BRCA1 Mutations Disrupt Ovarian Blood Vessel Formation Before Cancer Develops

Heterozygous BRCA1 Mutations Disrupt Ovarian Blood Vessel Formation Before Cancer Develops

November 22, 2026

Comparative Genomics Unveils Evolutionary Lineages and Stress Genes Across Four Vigna Legumes

November 22, 2026

STAG1 Gene Variants Impair Genome Stability and Disrupt Human Neurodevelopment

November 22, 2026
Please login to join discussion

POPULAR NEWS

  • Regional Climate Simulations Reveal Non-Uniform Future Shifts in Canadian Maximum Precipitation

    Regional Climate Simulations Reveal Non-Uniform Future Shifts in Canadian Maximum Precipitation

    29 shares
    Share 12 Tweet 7
  • Single-Cell Sequencing Uncovers How STAP2 Drives Diabetic Retinal Vascular Dysfunction

    29 shares
    Share 12 Tweet 7
  • Heterozygous BRCA1 Mutations Disrupt Ovarian Blood Vessel Formation Before Cancer Develops

    29 shares
    Share 12 Tweet 7
  • Portable Microfluidic Platform Quantifies Post-Transplant Viral Infections at Point of Care

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Regional Climate Simulations Reveal Non-Uniform Future Shifts in Canadian Maximum Precipitation

Single-Cell Sequencing Uncovers How STAP2 Drives Diabetic Retinal Vascular Dysfunction

Heterozygous BRCA1 Mutations Disrupt Ovarian Blood Vessel Formation Before Cancer Develops

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.